Published on : Nov 30, 2016
ALBANY, NY, Nov 30, 2016: The study includes a detailed discussion on factors that are having a strong impact on the market, be it positive or negative. It then enlists the future scope of the market by analyzing the opportunities present in the market. The current and past market size has been given and are used to determine the estimated market size in the coming years.
The report analyzes the various developments taking place in the ophthalmology market and discusses the current company market landscape. It begins with a brief introduction on ophthalmology, pathophysiology, symptoms, and an overview of pharmacotherapy for key diseases. The study also assesses licensing and co-development of ophthalmology therapies. The benchmarking of deals, both first in class and non-first in class products are discussed. The report also identifies commercial opportunities in the ophthalmology deals landscape by analyzing trends and also enlisting ophthalmology therapies that can be a potential investment opportunity.
The global ophthalmology therapeutics market is driven by the rising number of visually impaired people across the globe. Many of the visual impairments can be detected, cured, and even prevented. This report thus, discusses the many recent improvements in the diagnosis of impairments and advancements in product developments, delivery devices, novel formulations, and development of new drug classes that help in the treatment of various symptoms of eye conditions. The only factor restricting the growth of the market is a lack of awareness regarding the ophthalmology therapeutics available in the market.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=869173
The report discusses the clinical and commercial landscape of diabetic macular edema, diabetic retinopathy, age-related macular degeneration, dry eye syndrome, and glaucoma. It also discusses the symptoms, treatment options, and diagnosis of these diseases. It assesses regulatory and reimbursement policy shifts that are favoring the first-in-class product innovation.
Key players in the global ophthalmology therapeutics market such as Roche, Alcon (Novartis), Allergan, Pfizer, and Merck & Co. are striving to mark in glaucoma and age-related macular degeneration (AMD). Many of the leading drugs in the industry are expected to face patent expiry in the coming years. This is expected to enable innovative formulation specialists to generate combination therapies and generic drugs that are cost-effective. This is expected to compel manufacturers to protect their franchises by developing new classes of drugs and address areas of unmet needs. A key trend observed among players in the market is strategic alliances in order to ensure a strong hold over the market and capture a larger portion of the market share.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org